NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Heidelberg Pharma Executive Management Board Changes and New CEO Appointment
TL;DR
Heidelberg Pharma appoints Dr. Jeffery Liu as CEO, bringing 25 years of industry expertise to advance their ATAC cancer therapy technology and strengthen the company's market position.
Heidelberg Pharma's leadership transition involves Dr. Liu moving from Supervisory Board to CEO through a structured process compliant with German Stock Corporation Act provisions.
This leadership change at Heidelberg Pharma aims to accelerate development of innovative cancer therapies that could improve treatment outcomes for patients worldwide.
Heidelberg Pharma uses Amanitin from death cap mushrooms in their ATAC technology to create targeted cancer therapies that specifically kill diseased cells.
Found this article helpful?
Share it with your network and spread the knowledge!
Heidelberg Pharma has appointed Dr. Dongzhou Jeffery Liu as Chairman of the Executive Management Board and Chief Executive Officer, replacing Professor Andreas Pahl, effective immediately for his appointment as CEO and December 24, 2025 for his permanent role as Chairman.
The Supervisory Board believes Dr. Liu will further strengthen Heidelberg Pharma's profile with great dedication, building on the scientific foundation established by Professor Pahl, who developed the company's unique Amanitin-based ADC technology.
Dr. Liu is currently Chief Scientific Officer and President of Huadong Global Development at Huadong Medicine in China, with over 25 years of pharmaceutical industry experience including positions at GlaxoSmithKline, Wyeth (now Pfizer), and Forest Labs (now Abbvie), specializing in clinical and preclinical research & development of medicinal products including ADCs.
Dr. Liu's permanent appointment as Chairman of the Executive Management Board and Chief Executive Officer becomes effective on December 24, 2025, with a transition period from November 24, 2025 until December 23, 2025 where he serves as a deputy member to the Executive Management Board.
Heidelberg Pharma develops Antibody Drug Conjugates (ADCs) using its proprietary ATAC technology, which utilizes Amanitin from the green death cap mushroom as a payload to create targeted cancer treatments that combine antibody specificity with toxin efficacy.
The company's lead candidate is HDP-101 (pamlectabart tismanitin), a BCMA ATAC for multiple myeloma with FDA Orphan Drug and Fast Track Designation, plus HDP-102 for Non-Hodgkin Lymphoma, HDP-103 for metastatic castration-resistant prostate cancer, and HDP-104 for gastrointestinal tumors.
Professor Pahl served for many years on the Executive Management Board and used his scientific expertise to shape the company's unique Amanitin-based ADC technology, developing the lead clinical stage ADC project HDP-101.
Dr. Liu expressed confidence that Heidelberg Pharma's ATAC technology has great potential for effective cancer treatment based on latest clinical data with HDP-101, and he looks forward to leading the company toward developing a new generation of ADC products.
During the transition period until December 23, 2025, Dr. Liu will be seconded as a deputy member to the Executive Management Board pursuant to section 105 (2) of the German Stock Corporation Act (Aktiengesetz).
Heidelberg Pharma is the first company to use Amanitin from the green death cap mushroom in cancer therapy, representing a new therapeutic modality that works through a biological mechanism of action different from traditional ADC payloads.
Curated from NewMediaWire
